Telomir Pharmaceuticals
TELO
25 hedge funds and large institutions have $1.74M invested in Telomir Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 2 closing their positions.
900% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 2
417% more capital invested
Capital invested by funds: $337K → $1.74M (+$1.4M)
257% more funds holding
Funds holding: 7 → 25 (+18)
0.95% more ownership
Funds ownership: 0.27% → 1.22% (+0.95%)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$548K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$414K |
| 3 |
Bank of New York Mellon
New York
|
+$313K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$179K |
| 5 |
New York State Common Retirement Fund
Albany,
New York
|
+$146K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lido Advisors
Los Angeles,
California
|
-$77.3K |
| 2 |
Citigroup
New York
|
-$69.8K |
| 3 |
JP Morgan Chase
New York
|
-$3.46K |
| 4 |
FIA
FNY Investment Advisers
New York
|
-$77 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Lido Advisors
Los Angeles,
California
| – | -$77.3K | -15,000 | Closed |
|
|
FIA
27
FNY Investment Advisers
New York
| – | -$77 | -14,900 | Closed |
|
TELO Hedge Fund Activity: Q2 2024 in Review
25 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Telomir Pharmaceuticals (TELO) for Q2 2024, worth a combined $1.74M — up 417% from $337K a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new TELO positions and 2 closed out — a net gain of 18 holders — while 2 added to existing stakes and 2 trimmed.
The largest buyer was BlackRock, opening a new position worth an estimated $548K. The largest seller was Lido Advisors, exiting entirely with an estimated $77.3K sold.
- 25 institutional investors held Telomir Pharmaceuticals (TELO) as of Q2 2024, up from 7 in Q1 2024.
- Funds reported $1.74M of Telomir Pharmaceuticals stock for Q2 2024, up 417% quarter-over-quarter.
- 20 funds opened new Telomir Pharmaceuticals positions in Q2 2024 and 2 closed out, a net change of +18 holders.
- The largest Telomir Pharmaceuticals buyer in Q2 2024 was BlackRock, an estimated $548K added.
- The largest Telomir Pharmaceuticals seller in Q2 2024 was Lido Advisors, an estimated $77.3K sold.
Based on aggregated 13F filings for Q2 2024.